Motley Fool Asset Management LLC Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Motley Fool Asset Management LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,377 shares of the medical device company’s stock after purchasing an additional 730 shares during the period. Motley Fool Asset Management LLC’s holdings in DexCom were worth $1,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Bank of New Hampshire purchased a new position in DexCom in the first quarter worth approximately $1,508,000. abrdn plc grew its stake in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares in the last quarter. Cerity Partners LLC grew its stake in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of DexCom by 21.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after purchasing an additional 310,728 shares in the last quarter. Finally, Alberta Investment Management Corp grew its stake in shares of DexCom by 27.0% during the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock worth $40,123,000 after purchasing an additional 68,723 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $1.88 on Wednesday, reaching $67.82. The company’s stock had a trading volume of 11,123,763 shares, compared to its average volume of 3,519,284. The stock’s 50-day moving average is $111.54 and its two-hundred day moving average is $122.55. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market capitalization of $27.18 billion, a P/E ratio of 43.76, a PEG ratio of 2.04 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.34 earnings per share. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.7 EPS for the current year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 3,483 shares of company stock valued at $401,450 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on DXCM shares. Oppenheimer lowered their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. UBS Group lowered their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, Robert W. Baird cut shares of DexCom from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $161.00 to $80.00 in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $111.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.